CELIA
OREJA GUEVARA
Profesora asociada de Ciencias de la Salud
Monash University
Melbourne, AustraliaPublications in collaboration with researchers from Monash University (25)
2024
-
Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies
Journal of neurology, Vol. 271, Núm. 1, pp. 472-485
2021
-
Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis
Neurology, Vol. 96, Núm. 24, pp. E2989-E3002
2020
-
Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder
Multiple Sclerosis and Related Disorders, Vol. 38
-
Delay from treatment start to full effect of immunotherapies for multiple sclerosis
Brain, Vol. 143, Núm. 9, pp. 2742-2756
2017
-
Contribution of different relapse phenotypes to disability in multiple sclerosis
Multiple Sclerosis, Vol. 23, Núm. 2, pp. 266-276
-
Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis
Journal of Neurology, Neurosurgery and Psychiatry, Vol. 88, Núm. 3, pp. 196-203
-
Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice
Multiple Sclerosis, Vol. 23, Núm. 10, pp. 1346-1357
-
Towards personalized therapy for multiple sclerosis: Prediction of individual treatment response
Brain, Vol. 140, Núm. 9, pp. 2426-2443
2016
-
Defining secondary progressive multiple sclerosis
Brain, Vol. 139, Núm. 9, pp. 2395-2405
-
Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis
Journal of Neurology, Neurosurgery and Psychiatry, Vol. 87, Núm. 12, pp. 1343-1349
-
The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis
Multiple Sclerosis, Vol. 22, Núm. 4, pp. 520-532
2015
-
BREMSO: A simple score to predict early the natural course of multiple sclerosis
European Journal of Neurology, Vol. 22, Núm. 6, pp. 981-989
-
Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis
Multiple Sclerosis, Vol. 21, Núm. 9, pp. 1159-1171
-
Comparative efficacy of switching to natalizumab in active multiple sclerosis
Annals of Clinical and Translational Neurology, Vol. 2, Núm. 4, pp. 373-387
-
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis
JAMA Neurology, Vol. 72, Núm. 4, pp. 405-413
-
Defining reliable disability outcomes in multiple sclerosis
Brain, Vol. 138, Núm. 11, pp. 3287-3298
-
Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry
Multiple Sclerosis Journal - Experimental, Translational and Clinical, Vol. 1
-
Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis
Annals of Neurology, Vol. 77, Núm. 3, pp. 425-435
2014
-
Predictors and dynamics of postpartum relapses in women with multiple sclerosis
Multiple Sclerosis Journal, Vol. 20, Núm. 6, pp. 739-746